Sherman Act Cut From Clot Drug Suit, State Claims Survive

By Dani Kass · December 6, 2018, 8:31 PM EST

A Tennessee federal judge has freed Momenta Pharmaceuticals Inc. and Sandoz Inc. from Sherman Act allegations that they conspired to monopolize the market for the blood clot drug Lovenox and its...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

The Hospital Authority of Metropolitan Government of Nashville and Davidson County, Tennessee v. Momenta Pharmaceuticals, Inc. et al

Case Number

Court

Tennessee Middle

Nature of Suit

Anti-Trust

Date Filed

October 14, 2015

Recent Articles By Dani

March 12, 2025
Law360 Cheat Sheet: Novartis' Fight Over Generic Entresto
March 05, 2025
Pfizer, BioNTech Get PTAB To Invalidate Moderna Vaccine IP
February 24, 2025
Fed. Circ. Shouldn't Assume Doctors Read Labels, Profs Say
January 28, 2025
GSK Urges Del. Judge To Enhance $235M Skinny Label Win
January 13, 2025
Supreme Court Turns Away IP Safe Harbor Dispute
January 01, 2025
Patent Cases To Watch In 2025
December 20, 2024
Sens. Aim To Protect Generics With Skinny Labels In New Bill
December 18, 2024
Patent Limits For Biosimilar Litigation Lands In Spending Bill
December 18, 2024
Amgen Hit With $50M Infringement Verdict Over Leukemia Drug
December 04, 2024
Fed. Circ. Judge Condemns 'Nonsense' Law In Antibody Fight